Evidence map›Paper›PMID 42254725›Full record

ArticleJournal of human immunity2026

The burden of severe leukocyte adhesion deficiency, type I (LAD-I): A multiple-case study from the caregiver's perspective.

Meaghan O'Connor, Clarissa Simas, Michael Keith, Miranda Bailey, Kristi Jackson, Leslie Blake, Maria Chitty Lopez

Abstract read
In one paragraph

Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meaghan O'ConnorIQVIA, Durham, NC, USA.ORCID https://orcid.org/0000-0001-6576-2952
Clarissa SimasIQVIA, Durham, NC, USA.ORCID https://orcid.org/0000-0003-0035-8419
Michael KeithRocket Pharmaceuticals, Cranbury, NJ, USA.ORCID https://orcid.org/0009-0004-5151-0374
Miranda BaileyRocket Pharmaceuticals, Cranbury, NJ, USA.ORCID https://orcid.org/0009-0007-3616-6263
Kristi JacksonIQVIA, Durham, NC, USA.ORCID https://orcid.org/0000-0003-0081-5165
Leslie BlakeRocket Pharmaceuticals, Cranbury, NJ, USA.ORCID https://orcid.org/0000-0001-8275-5471
Maria Chitty LopezRocket Pharmaceuticals, Cranbury, NJ, USA.ORCID https://orcid.org/0000-0002-5006-8623

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukocyte adhesion deficiency, type I (LAD-I) is a rare inborn error of immunity characterized by recurrent, severe infections/inflammation and poor wound healing. Little is known about the patient/family experience of severe LAD-I. We conducted a multiple-case study exploring the burdens of illness, caregiving, and treatment in severe LAD-I. Nine caregivers (parents) representing five families with ≥1 child with severe LAD-I participated in individual, in-depth interviews. Memoing and inductive/deductive coding were used to analyze and compare each family's experience. The caregivers described frequent and severe infections, physical and social restrictions, a complex journey to diagnosis, rearranging life around severe LAD-I, financial strain, isolation, and uncertainty. Treatment burden varied by treatment type. This multiple-case study highlights how severe LAD-I affects patients and families. As the first study to address the humanistic burden of LAD-I in patients and caregivers, it is an important contribution to the literature on LAD-I and qualitative methods for investigating the burden of rare disease on families.

Identifiers

PMID42254725
PMCPMC13235583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.